TMDX
TransMedics Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TMDX
Transmedics Group, Inc.
A medical technology company that transforming organ transplant therapy for end-stage lung, heart, and liver failure
200 Minuteman Road, Andover, Massachusetts 01810
--
TransMedics Group, Inc., was registered in August 1998. The company is a commercial-stage medical technology company that provides organ transplant treatment to patients with end-stage organ failure in multiple disease states. The company developed the catenary to replace the decades-old standard of care. The company's innovative catenary technology replicates many aspects of the natural living and functional environment of external human organs. OCS represents a change in approach that transplants preservation from a static state to a dynamic environment, enabling new functions, including organ optimization and evaluation.
Earnings Call
Q1/2025
Estimate EPS0.24
Actual EPS0.7
Estimate Revenue123.39M
Actual Revenue143.50M
Liver Growth vs. Clinical Trials: Contradictory Insights from the Latest Earnings Call
May 19,2025 07:38
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.43
Actual EPS0.92
Estimate Revenue147.75M
Actual Revenue157.40M
TransMedics' Q2 2025: Unraveling Contradictions on Clinical Trials, Market Share, and Seasonality
Jul 31,2025 12:42
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.37
Actual EPS0.66
Estimate Revenue144.97M
Actual Revenue143.80M
TransMedics' Q3 2025 Earnings Call: Contradictions Emerge on Seasonality, Trial Revenue, and 2026 Growth Projections
Oct 30,2025 12:11
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TMDX has released its 2025 Q3 earnings. EPS was reported at 0.66, versus the expected 0.37, beating expectations. The chart below visualizes how TMDX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TMDX has released its 2025 Q3 earnings report, with revenue of 143.82M, reflecting a YoY change of 32.24%, and net profit of 24.32M, showing a YoY change of 476.83%. The Sankey diagram below clearly presents TMDX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
